← FDA DRUG APPROVALS

FDA ANDA · ANDA219221

IPRATROPIUM BROMIDE

Sponsor: RUBICON RESEARCH

APPLICATION
ANDA219221
TYPE
ANDA
ORIGINAL APPROVAL
2024-11-15
LATEST ACTION
2024-11-15
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Prescription

Products

IPRATROPIUM BROMIDEPrescription
IPRATROPIUM BROMIDE 0.042MG/SPRAY · SPRAY, METERED · NASAL

Approval history

2024-11-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →